Boehringer Ingelheim International Gmbh

Ablynx N.v.

Joachim Boucneau

Marie-Ange Buyse

Erik Depla

Rene Georg Ott

Andreas Gschwind

Gino Van Heeke

Peter Casteels

Eric Borges

Evelyn De Tavernier

Pascal Merchiers

Joost Kolkman

Frederik Stevenaert

Bispecifc binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.

Bispecific binding molecules binding to VEGF and Ang2

The present invention relates to amino acid sequences, compounds and polypeptides binding to tumor necrosis factor alpha ('TNF' or 'TNF-alpha'). In particular, the present invention relates to improved heavy-chain immunoglobulin single variable domains (also referred to herein as &#x201c;ISV's&#x201d; or &#x201c;ISVDs&#x201d;) binding to tumor necrosis factor alpha, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such ISVDs, collectively TNF binders. Other aspects, embodiments, features, uses and advantages of the invention will be clear to the skilled person based on the disclosure herein.

TNF binders

Bispecific binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.

Bispecific binding molecules binding to VEGF and ANG2

Growing community of inventors

De Pinte, Belgium

Joachim Boucneau